Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Adds CN¥463m in Market Cap and Insiders Have a 76% Stake in That Gain
Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) Adds CN¥463m in Market Cap and Insiders Have a 76% Stake in That Gain
Key Insights
主要見解
- Insiders appear to have a vested interest in Aurisco PharmaceuticalLtd's growth, as seen by their sizeable ownership
- A total of 2 investors have a majority stake in the company with 70% ownership
- Analyst forecasts along with ownership data serve to give a strong idea about prospects for a business
- 內部人似乎對奧銳特的成長有着既得利益,這可以從他們持有的大量股份中看出。
- 總共有2位投資者擁有奧銳特70%的所有權。
- 分析師預測以及所有者數據可以給我們提供有關業務前景的強烈想法。
A look at the shareholders of Aurisco Pharmaceutical Co.,Ltd. (SHSE:605116) can tell us which group is most powerful. And the group that holds the biggest piece of the pie are individual insiders with 76% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
看看奧銳特藥業股份有限公司(SHSE:605116)的股東名冊,可以告訴我們哪個群體最有實力。而擁有最大份額的群體是個人內部人,持有76%的股權。換句話說,這個群體有可能從他們對公司的投資中獲得最大的收益(或虧損)。
Clearly, insiders benefitted the most after the company's market cap rose by CN¥463m last week.
顯然,在公司市值上週增長了46300萬人民幣後,內部人獲益最大。
In the chart below, we zoom in on the different ownership groups of Aurisco PharmaceuticalLtd.
在下圖中,我們放大了奧銳特藥業股份有限公司的不同所有權群體。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240802/0-762c4fc2d734464980caefbb802897ea-0-a8466b91f4db33327419f808f31559ab.png/big)
What Does The Institutional Ownership Tell Us About Aurisco PharmaceuticalLtd?
機構持股信息揭示了哪些關於奧銳特的藥業股份有限公司的品牌價值。
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時會針對一個基準進行衡量,因此一旦某隻股票被納入主要指數,他們通常會更加熱衷於該股票。我們預計大多數公司都會有一些機構在登記簿上,尤其是那些正在增長的公司。
Aurisco PharmaceuticalLtd already has institutions on the share registry. Indeed, they own a respectable stake in the company. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Aurisco PharmaceuticalLtd, (below). Of course, keep in mind that there are other factors to consider, too.
奧銳特藥業股份有限公司的股份登記簿上已經有一些機構持股。實際上,他們持有公司相當可觀的股份。這表明該公司在投資界具有一定的信譽度。但是,依賴機構投資者所帶來的假定加持需要慎重考慮。他們也有時會做錯事。如果兩個大型機構投資者同時試圖拋售一支股票,股價大跌是很常見的。因此,最好查看奧銳特藥業股份有限公司過去的收益軌跡。當然,也要記住還有其他因素需要考慮。
![big](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240802/0-762c4fc2d734464980caefbb802897ea-1-6345f1acc664069441a1097d465f0ccd.png/big)
Aurisco PharmaceuticalLtd is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Zhien Peng with 38% of shares outstanding. For context, the second largest shareholder holds about 32% of the shares outstanding, followed by an ownership of 2.8% by the third-largest shareholder. Peijing Qiu, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors. Additionally, the company's CEO Dingjun Chu directly holds 0.8% of the total shares outstanding.
奧銳特藥業股份有限公司不是對沖基金公司所有。我們的數據顯示,持有股份的最大股東是彭志恩,持股38%。爲了提供背景,持有第二多股份數量的股東持股約32%,第三多股東的持股爲2.8%。而第三大股東邱培靖也擔任董事會成員職務。此外,該公司CEO褚定軍直接持有公司總股本的0.8%。
To make our study more interesting, we found that the top 2 shareholders have a majority ownership in the company, meaning that they are powerful enough to influence the decisions of the company.
爲了使我們的研究更有趣,我們發現前2名股東擁有該公司的大部分所有權,這意味着他們足夠強大,可以影響公司的決策。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
研究機構所有權是衡量和過濾股票預期表現的好方法。通過研究分析師的情緒也可以實現同樣的目的。由於有相當數量的分析師涵蓋這支股票,因此了解他們對未來的整體看法可能會有所幫助。
Insider Ownership Of Aurisco PharmaceuticalLtd
奧銳特藥業股份有限公司內部人持股情況
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
雖然「內部人士」的明確定義具有主觀性,但幾乎所有人都認爲董事會成員是內部人士。公司管理業務,但首席執行官即使是董事會成員,也要向董事會負責。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內部人持股情況表明領導層思考和公司真正所有者一樣時,內部所有權是積極的。然而,高達內部人士所有權也可能爲公司內的小團體帶來巨大的權力。在某些情況下,這可能是負面的。
Our most recent data indicates that insiders own the majority of Aurisco Pharmaceutical Co.,Ltd.. This means they can collectively make decisions for the company. Given it has a market cap of CN¥9.9b, that means insiders have a whopping CN¥7.5b worth of shares in their own names. Most would argue this is a positive, showing strong alignment with shareholders. You can click here to see if they have been selling down their stake.
我們最近的數據顯示,內部人擁有奧銳特藥業股份有限公司的大部分股份。這意味着他們可以集體爲公司做出決策。考慮到它的市值爲99億人民幣,這意味着內部人自己名下擁有75億人民幣的股份。大多數人會認爲這是正面的,顯示股東的強大對其有好處。單擊此處查看他們是否一直在減持股份。
General Public Ownership
一般大衆所有權
With a 15% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Aurisco PharmaceuticalLtd. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
普通公衆持有奧銳特藥業股份有限公司的15%股份,這主要是由個人投資者組成的。這種持股比例相當可觀,但如果決策與其他大股東不一致,可能無法改變公司政策。
Private Company Ownership
私有公司的所有權
Our data indicates that Private Companies hold 4.1%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
我們的數據顯示,私人公司持有該公司4.1%的股份。私人公司可能是相關方。有時內部人員通過控股私人公司而擁有公開公司的利益,而不是以個人身份擁有。雖然很難得出任何概括性結論,但這值得進一步研究。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Aurisco PharmaceuticalLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Aurisco PharmaceuticalLtd (at least 1 which is a bit unpleasant) , and understanding them should be part of your investment process.
了解一家公司的股東不同群體是值得思考的,但要更好地了解奧銳特藥業股份有限公司,我們需要考慮很多其他因素。例如,始終存在的投資風險威脅。我們已經確定了奧銳特藥業股份有限公司的2個警告信號(至少有1個有點不好),了解它們應該成爲您的投資過程的一部分。
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
最終,未來最重要。您可以在這份關於該公司分析師預測的免費報告中獲取有關信息。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的數據是使用最後一個財務報表日期結束的爲期12個月的數據計算的。這可能與全年年度報告數據不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。